Advanced Functional Materials,
Journal Year:
2024,
Volume and Issue:
34(38)
Published: June 12, 2024
Abstract
Photoresponsive
drug
delivery
systems
(PDDSs)
have
emerged
as
a
promising
toolbox
for
delivery,
offering
precise
control
over
the
site,
duration,
and
dosage
of
light‐triggered
medication.
It
allows
controlled
release,
photo‐triggered
targeting,
diagnosis,
treatment,
improving
precision
efficacy
therapies
various
diseases.
Despite
progress
in
designing
different
PDDSs,
clinical
translation
has
been
limited
due
to
obstacles.
Herein,
this
review
article
focuses
on
three
critical
challenges
PDDSs:
1)
accumulation
at
diseased
lesions,
2)
light
irradiation,
3)
penetration
tissues.
Also,
summarizes
discusses
current
advancements
strategies
address
these
challenges.
Overall,
it
emphasizes
need
clarify
from
bench
bedside
develop
enhance
therapeutic
outcomes,
increase
compatibility
patient
compliance,
unlock
possibilities
therapies.
Journal of the American Chemical Society,
Journal Year:
2024,
Volume and Issue:
146(28), P. 19434 - 19448
Published: July 3, 2024
Immuno-photodynamic
therapy
(IPDT)
has
emerged
as
a
new
modality
for
cancer
treatment.
Novel
photosensitizers
can
help
achieve
the
promise
inherent
in
IPDT,
namely,
complete
eradication
of
tumor
without
recurrence.
We
report
here
small
molecule
photosensitizer
conjugate,
LuCXB.
This
IPDT
agent
integrates
celecoxib
(cyclooxygenase-2
inhibitor)
moiety
with
near-infrared
absorbing
lutetium
texaphyrin
photocatalytic
core.
In
aqueous
environments,
two
components
LuCXB
are
self-associated
through
inferred
donor-acceptor
interactions.
A
consequence
this
intramolecular
association
is
that
upon
photoirradiation
730
nm
light,
produces
superoxide
radicals
(O2-•)
via
type
I
photodynamic
pathway;
provides
first
line
defense
against
while
promoting
IPDT.
For
vivo
therapeutic
applications,
we
prepared
CD133-targeting,
aptamer-functionalized
exosome-based
nanophotosensitizer
(Ex-apt@LuCXB)
designed
to
target
stem
cells.
Ex-apt@LuCXB
was
found
display
good
photosensitivity,
acceptable
biocompatibility,
and
robust
targetability.
Under
conditions
photoirradiation,
acts
amplify
exerting
significant
antitumor
effect
both
liver
breast
mouse
models.
The
observed
effects
attributed
synergistic
mechanism
combines
antiangiogenesis
photoinduced
immunotherapy.
Advanced Science,
Journal Year:
2023,
Volume and Issue:
11(11)
Published: Dec. 31, 2023
Abstract
Mild
magnetic
hyperthermia
therapy
(MMHT)
holds
great
potential
in
treating
deep‐seated
tumors,
but
its
efficacy
is
impaired
by
the
upregulation
of
heat
shock
proteins
(HSPs)
during
treatment
process.
Herein,
Lac‐FcMOF,
a
lactose
derivative
(Lac‐NH
2
)
modified
paramagnetic
metal‐organic
framework
(FcMOF)
with
property
and
thermal
stability,
has
been
developed
to
enhance
MMHT
therapeutic
efficacy.
In
vitro
studies
showed
that
Lac‐FcMOF
aggravates
two‐way
regulated
redox
dyshomeostasis
(RDH)
via
magnetothermal‐accelerated
ferricenium
ions‐mediated
consumption
glutathione
ferrocene‐catalyzed
generation
∙OH
induce
oxidative
damage
inhibit
protein
70
(HSP70)
synthesis,
thus
significantly
enhancing
anti‐cancer
MMHT.
Aggravated
RDH
promotes
peroxidase
4
inactivation
lipid
peroxidation
promote
ferroptosis,
which
further
synergizes
H22‐tumor‐bearing
mice
treated
under
alternating
field
(AMF)
demonstrated
90.4%
inhibition
tumor
growth.
This
work
therefore
provides
new
strategy
for
simple
construction
agent
enables
efficient
downregulating
HSPs
promoting
ferroptosis
through
aggravation
RDH.
Pharmacological Research,
Journal Year:
2024,
Volume and Issue:
203, P. 107150 - 107150
Published: March 21, 2024
Cancer,
with
its
diversity,
heterogeneity,
and
complexity,
is
a
significant
contributor
to
global
morbidity,
disability,
mortality,
highlighting
the
necessity
for
transformative
treatment
approaches.
Photodynamic
therapy
(PDT)
has
aroused
continuous
interest
as
viable
alternative
conventional
cancer
treatments
that
encounter
drug
resistance.
Nanotechnology
brought
new
advances
in
medicine
shown
great
potential
delivery
treatment.
For
precise
efficient
therapeutic
utilization
of
such
tumor
approach
high
spatiotemporal
selectivity
minimal
invasiveness,
carrier-free
noncovalent
nanoparticles
(NPs)
based
on
chemo-photodynamic
combination
essential.
Utilizing
natural
products
foundation
nanodrug
development
offers
unparalleled
advantages,
including
exceptional
pharmacological
activity,
easy
functionalization/modification,
well
biocompatibility.
The
natural-product-based,
carrier-free,
NPs
revealed
excellent
synergistic
anticancer
activity
comparison
free
photosensitizers
bioactive
products,
representing
an
favorable
avenue
improve
efficacy.
Herein,
comprehensive
summary
current
strategies
representative
application
examples
past
decade
(such
paclitaxel,
10-hydroxycamptothecin,
doxorubicin,
etoposide,
combretastatin
A4,
epigallocatechin
gallate,
curcumin)
therapy.
We
highlight
insightful
design
synthesis
smart
aim
enhance
PDT
Meanwhile,
we
discuss
future
challenges
opportunities
associated
these
provide
enlightenment,
spur
innovative
ideas,
facilitate
PDT-mediated
clinical
transformation.
Small,
Journal Year:
2024,
Volume and Issue:
unknown
Published: June 5, 2024
Abstract
Herein,
a
dual‐sensitizer
prodrug,
named
pro‐THPC,
has
been
designed
to
function
as
both
photosensitizer
and
sonosensitizer
prodrug
for
precise
antitumor
combination
therapy
with
minimized
skin
phototoxicity.
Pro‐THPC
could
be
activated
by
glutathione
(GSH)
release
the
dual‐sensitizer,
THPC,
which
simultaneously
switches
on
fluorescence
emission
combined
capabilities
of
photodynamic
(PDT)
sonodynamic
(SDT).
is
further
formulated
into
nanoparticles
(NPs)
water
dispersity
enable
in
vivo
applications.
In
imaging
shows
that
pro‐THPC
NPs
group
exhibits
significantly
higher
tumor‐to‐normal
tissue
ratio
(
T
/
N
)
=
5.2
±
0.55)
compared
“always
on”
THPC
2.9
0.47)
co‐administrated
GSH
synthesis
inhibitor
(buthionine
sulfoximine,
BSO)
3.2
0.63).
addition,
generation
dual‐sensitizer's
reactive
oxygen
species
(ROS)
effectively
confined
within
tumor
tissues
due
relatively
strong
correlation
between
ROS
emission.
studies
demonstrate
remarkable
efficacy
eradicate
tumors
through
PDT
SDT
while
reducing
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
36(24)
Published: Feb. 28, 2024
Abstract
The
insufficient
exposure
sites
and
active
site
competition
of
multienzyme
are
the
two
main
factors
to
hinder
its
therapeutic
effect.
Here,
a
phase‐junction
nanomaterial
(amorphous‐crystalline
Cu
x
S–Ag
2
S)
is
designed
prepared
through
simple
room
temperature
ion‐exchange
process.
A
small
amount
Ag
+
added
into
7
S
4
nanocrystals,
which
transforms
amorphous
phased
produces
crystalline
simultaneously.
In
this
structure,
overhanging
bonds
on
surface
provide
abundant
for
optimizing
activity.
Meanwhile,
state
enhances
photothermal
effect
non‐radiative
relaxation,
due
low
thermal
resistance,
forms
significant
gradient
unlock
optimized
thermo‐electrodynamic
therapy.
Furthermore,
benefiting
from
high
asymmetry
state,
material
spin‐polarized
that
can
effectively
inhibit
electron–hole
recombination.
way,
thermoelectric
facilitate
enzyme‐catalyzed
cycle
by
providing
electrons
holes,
enabling
an
enhanced
coupling
therapy
with
activity,
induces
excellent
anti‐tumor
performance.
More
importantly,
catalytic
process
simulated
density‐functional
theory
proves
alleviates
burden
favorable
adsorption
O
prevents
competition.
Nano Letters,
Journal Year:
2024,
Volume and Issue:
24(27), P. 8287 - 8295
Published: June 28, 2024
Organic
dyes
with
simultaneously
boosted
near-infrared-II
(NIR-II)
fluorescence,
type
I
photodynamic
therapy
(PDT),
and
photothermal
(PTT)
in
the
aggregate
state
are
still
elusive
due
to
unclear
structure-function
relationship.
Herein,
electron-withdrawing
substituents
introduced
at
5-indolyl
positions
of
BODIPY
form
tight
J-aggregates
for
enhanced
NIR-II
fluorescence
PDT/PTT.
The
introduction
an
electron-rich
julolidine
group
